Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 26, 2019

View Archived Issues

Rocket Pharmaceuticals announces IMPD clearance of RP-L301 gene therapy

Sympathetic nervous system can protect from autoimmunity

A cure for the common cold, and paralysis

circRNA-104718 promotes hepatocellular carcinoma progression through miR-218-5p targeting

Galapagos initiates phase I trial with GLPG-3970

[68Ga]PCTA-DSPE radiolabeled chelator for atherosclerosis PET imaging

Antimelanoma DNA vaccine/oncolytic adenovirus combination greatly enhances vaccine efficacy

Ectopic expression of human melanopsin in RGCs restores visual function in animal models

Results presented from phase I/II MEVITEM study of vismodegib plus temozolomide

Promising cohort 1 data from phase I trial of ivosidenib and vorasidenib in IDH1-mutant glioma

SAP130 as novel noninvasive biomarker in Crohn's Disease

DL-001, a novel rapamycin analogue with highly selective mTORC1 inhibitor activity in vivo

First patient dosed in phase III TRuE-V clinical trial program of ruxolitinib cream

LIDDS presents preliminary data from phase IIb LPC-004 study of Liproca Depot

Promising interim data presented from phase I/IIa study of AstroRx cell therapy in patients with ALS

SARM1: a new therapeutic target for MS and other neurodegenerative disorders

New designer cytokine IC7Fc shows promise for type 2 diabetes

Inflazome divulges new NLRP3 inhibitors

PharmaResources discloses new HBV antivirals

Phase IIa study of EDP-305 in NASH meets primary endpoint

AzurRx reports phase II results for MS-1819 for exocrine pancreatic insufficiency in cystic fibrosis

Celgene International II Sarl synthesizes new PDE4 inhibitors

Tyme Technologies begins pivotal stage of TYME-88-Panc trial with SM-88

Beijing Scitech-Mq Pharmaceuticals divulges EGFR and HER2 inhibitors

Vaxart reports phase Ib data on oral bivalent norovirus vaccine

Sunshine Lake Pharma patents MAO-B inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 12, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...